Big Picture Bio, a London-based BioTech startup developing AI-designed combination therapies for cancer and other complex diseases, has emerged from stealth with a combined funding round of €2.55 million (£2.2…
drug
-
-
Md Babul Hosen/iStock via Getty Images The Food and Drug Administration approved Telix Pharmaceuticals’ (TLX) Pixclara, a radioactive imaging drug used to help evaluate patients with glioma, the company said…
-
monkeybusinessimages/iStock via Getty Images AbCellera Biologics (ABCL) is up ~35% in Monday morning trading after announcing top-line phase 2 data for ABCL635, its candidate for moderate-to-severe vasomotor symptoms (hot flashes)…
-
Investment
Wall Street Lifts Obesity Drug Targets for Eli Lilly and AbbVie as Medicare Coverage Expands
JPMorgan lifted Eli Lilly to $1,400 and AbbVie drew a string of target hikes as a new Medicare GLP-1 program widens access. Investorideas.com (www.investorideas.com newswire) a trusted platform for investing…
-
Lilly says experimental obesity drug delivered weight loss across all stages of menopause
-
An experimental drug that could be a breakthrough in the treatment of one of the deadliest known cancers is driving demand at clinics while awaiting full government approval. Daraxonrasib, a…
-
For the first time in its history, Medicare is about to cover weight-loss drugs. Starting July 1, seniors who qualify can get Wegovy or Zepbound for just $50 a month…
-
The pharmaceutical company updated its sales guidance for 2025, saying it now expects $62 billion in revenue for the year.
-
Investment
kopi-C with Pasture Holdings CEO: From pharma distributor to mask producer to drug delivery pioneer
kopi-C with Pasture Holdings CEO: From pharma distributor to mask producer to drug delivery pioneer In the early days of Covid-19, as the pandemic slowly became a reality, Singaporeans began…
-
Investment
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), today announced that it has completed its trial entitled “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple…
